Medical technology company Stryker Corp. said Thursday it has agreed to acquire K2M Group Holdings Inc. for $27.50 a share or a total equity value of $1.4 billion.
K2M was founded in 2004 and has become a player in the $10 billion market for technology to treat spinal disorders with annual sales of close to $300 million. “K2M brings to Stryker’s Spine division a highly complementary and innovative portfolio, which includes a strong position in the complex spine market,” Stryker said in a statement.
The deal is expected to close in the fourth quarter and will not have a material impact on Stryker’s EPS or adjusted EPS in 2018.
The company is sticking with its adjusted EPS guidance of $7.22 to $7.27.l K2M shares were halted for the news. Stryker shares were slightly lower, but have gained 11% in 2018, while the S&P 500 has gained 9%.
By Ciara Linnane
Source: MarketWatch
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.